Xillix' (Canada) half-year revenues up 128%:
This article was originally published in Clinica
In the six months ended February 28th, 1995, Xillix (Canada) reported revenues of Can$2.59 million, an increase of 128% compared with the first half of fiscal 1994. Product sales accounted for Can$1.46 million (up 59%): during the first half Xillix sold four LIFE Imaging Systems, 30 MicroImager digital cameras and two Automated Image Cytometer systems. Loss for the period was reduced slightly to Can$2.03 million from Can$2.53 million the year before. The Richmond, British Columbia-based company has recently completed a Can$7 million private placement.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.